Abstract CD47 is a signaling receptor for the matricellular protein thrombospondin-1 and a counter-receptor for signal regulatory protein-α (SIRPα) on macrophages. Following its initial discovery in 1992 as a cell surface protein that is overexpressed by ovarian carcinoma, elevated CD47 expression has emerged as a negative prognostic factor for a variety of cancers. CD47 is also a potential therapeutic target based on the ability of CD47 blockade to cause regression of tumors in mice, and a humanized CD47 antibody has recently entered phase I clinical trials. CD47 blockade may control tumor growth by inhibiting thrombospondin-1 signaling or by preventing inhibitory SIRPα signaling in tumor-associated macrophages. A recent publication by Lee et al. (Hepatology 60:179-191, 2014) provides evidence that blocking CD47 signaling specifically depletes tumor-initiating stem cells in hepatocellular carcinoma and implicates cathepsin-S/protease-activated receptor-2 signaling in mediating this therapeutic response.
Studies of the mechanisms underlying acquired resistance to conventional chemotherapy have been advanced by emergence of the cancer stem cell hypothesis (O'Connor et al. 2014 ). In most cancers, only a minor subpopulation of cells has the ability to form a new tumor when transplanted into healthy animals. These tumor-initiating cells (TICs) bear characteristic stem cell markers and have the property of self-renewal. TICs are more resistant to conventional chemotherapy, leading to rapid regrowth of tumors and, ultimately, treatment failure. Thus, new therapeutic strategies are needed to selectively kill TICs.
CD47 is a cell surface protein that exhibits elevated expression on a growing list of cancer types (Campbell et al. 1992; Chao et al. 2012; Willingham et al. 2012) . Consistent with high CD47 expression being a negative prognostic factor in some cancers, CD47 is expressed highly on TICs from these cancers. Treatment of tumor-bearing mice with antibodies that block CD47 signaling has produced impressive tumor regression when used alone or combined with existing therapeutics (Zhao et al. 2011; Chao et al. 2012; Willingham et al. 2012) , and humanized CD47 antibodies have recently entered human clinical trials (NCT02216409, NCT02367196). However, the mechanism by which these antibodies act remains controversial (Soto-Pantoja et al. 2012; Zhao et al. 2012) . One theory proposes that the antibodies prevent CD47 on the tumor cells from engaging SIRPα on tumor-associated macrophages . The inhibitory SIRPα signaling triggered by CD47 binding is well documented to inhibit the phagocytic activity of macrophages (Barclay and van den Berg 2014) . In this model, CD47 serves as a Bdon't eat me^signal on the tumor cells. On the other hand, SIRPα-independent models invoke CD47 signaling that cell-autonomously regulates tumor cell viability, resistance to therapy, or the ability of antibody or cytotoxic T cell immunity to eliminate tumor cells (Zhao et al. 2011; Boukhari et al. 2015; Soto-Pantoja et al. 2014; Lee et al. 2014) .
Based on their finding that CD47 is enriched on CD133 + / CD24 + TICs isolated from a hepatocellular carcinoma cell line and is elevated by serial passage in the presence of doxorubicin and cisplatin, Lee and colleagues examined cellautonomous mechanisms by which high CD47 expression confers chemoresistance and increases the stem cell character of TICs (Lee et al. 2014) . Microarray data identified elevated cathepsin-S mRNA in the TICs that was decreased when the cells differentiated and when CD47 expression was suppressed using a specific shRNA. CD47 expression correlated with that of cathepsin-S in hepatocellular carcinoma patient specimens and was shown to regulate cathepsin-S expression in TIC through activation of NFκB. Cathepsin-S in turn controlled TIC migration and invasion through activation of protease-activated receptor-2, which is a substrate for this protease. Finally, the authors demonstrated that antisense morpholino suppression of CD47 suppressed the growth and metastasis of hepatocellular carcinoma xenografts in nonobese diabetic (NOD)/SCID mice. Combination with doxorubicin treatment enhanced the activity of the morpholino. Although the latter experiments are consistent with the authors' proposed mechanism, the variant SIRPα expressed in NOD/SCID mice can recognize the human CD47 expressed by the hepatocellular carcinoma cells (Takenaka et al. 2007 ). Thus, loss of the Bdon't eat me^signal may also contribute to the observed therapeutic response.
These interesting results are consistent with another new publication that links CD47 signaling in glioblastoma cells to NFκB activation and the cyclin-dependent kinase inhibitor p16
INK4A (Boukhari et al. 2015) . In contrast to the cellautonomous beneficial effects of high CD47 expression in TICs, thrombospondin-1 signaling through CD47 limits selfrenewal and suppresses expression of the stem cell transcription factors cMyc, Sox2, Oct4, and Klf4 in nontransformed cells (Kaur et al. 2013 ). Further study is required to understand why CD47 differentially regulates cancer versus normal stem cells and to understand the role of the CD47 ligand thrombospondin-1, which is often silenced during malignant progression (Isenberg et al. 2009 ), in TIC maintenance.
